Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 5/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190443 | 0.93 | KMT2A (0.39) | JAK3KMT2AJAK2BTK | |
| SCHEMBL20774201 | 0.86 | KMT2A (0.61) | JAK3KMT2AEGFRITKBTK | |
| SCHEMBL3433250 | 0.86 | KMT2A (0.61) | JAK3KMT2AEGFRITKBTK | |
| SCHEMBL14674931 | 0.86 | JAK3 (0.56) | JAK3KMT2AEGFRITKJAK2 | |
| SCHEMBL14675141 | 0.86 | KMT2A (0.61) | JAK3KMT2AEGFRITKBTK | |
| SCHEMBL1783130 | 0.85 | KMT2A (0.43) | KMT2AEGFRBTK | |
| SCHEMBL12067315 | 0.84 | BTK (0.44) | JAK3BTK | |
| SCHEMBL17797630 | 0.83 | MAPK3 (0.53) | JAK3KMT2AEGFRITKBTK | |
| SCHEMBL14841407 | 0.82 | PIN1 (0.45) | JAK3KMT2AEGFRITKJAK1 | |
| SCHEMBL17388653 | 0.82 | PIN1 (0.45) | JAK3KMT2AEGFRITKJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582703-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2013-04-24 | — | — | EP | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK3 3/4885KMT2A 1187/4885EGFR 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.